Engineered estrogen receptor ligand-binding domain within the ΔRAF1-ERT fusion protein (ΔRAF1-ERT)

The engineered estrogen receptor ligand-binding domain (ER-LBD) within the ΔRAF1-ERT fusion protein is a synthetic molecular switch used to control the activity of the RAF1 kinase in research settings (Samuels et al., 1993). This domain, often referred to as ERT or ERT2, contains specific mutations such as G521R that render it insensitive to endogenous 17β-estradiol while maintaining high sensitivity to the synthetic ligand 4-hydroxytamoxifen (4-OHT) (Littlewood et al., 1995). In the absence of 4-OHT, the ER-LBD promotes the sequestration of the fusion protein into an inactive complex with heat shock proteins, such as Hsp90, which prevents the ΔRAF1 kinase from interacting with its downstream substrates. Upon the addition of 4-OHT, the ligand binds to the engineered LBD, inducing a conformational change that triggers the dissociation of the chaperone complex. This release allows the constitutively active ΔRAF1 domain to phosphorylate MEK, thereby activating the MAPK/ERK signaling pathway (Woods et al., 1997). This system is a vital tool in cancer research for modeling oncogenic signaling and studying the temporal effects of Raf-1 activation on cell proliferation, differentiation, and senescence.

Other names

ΔRaf-1:ERRaf-1:ER(T)Raf-ERΔRaf:ERERTERT2Modified estrogen receptor ligand-binding domain

4-hydroxytamoxifen binds to the engineered estrogen receptor ligand-binding domain, inducing a conformational change that releases the fusion protein from inhibitory heat shock protein complexes (e.g., Hsp90), thereby allowing the truncated RAF1 kinase to phosphorylate MEK and activate the MAPK/ERK signaling cascade.